Skip to main
CATX
CATX logo

CATX Stock Forecast & Price Target

CATX Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Perspective Therapeutics Inc. demonstrates a strong growth potential bolstered by its lead program, VMT-α-NET, which addresses a multi-billion-dollar market in neuroendocrine tumors (NET) with promising clinical data indicating significantly higher response rates compared to existing treatments such as Lutathera. The company’s proprietary use of the alpha-emitting isotope Lead-212 (212Pb) presents a competitive advantage due to its potential for improved safety and efficacy, fostering optimism about its therapeutic applications for cancer treatment. Furthermore, the increasing investment in the radiopharmaceutical sector, including notable financial commitments to isotope production, suggests a favorable market environment that could drive further advancements and interest in Perspective Therapeutics's innovative offerings.

Bears say

Perspective Therapeutics's stock outlook is negatively impacted by several factors, including the competitive landscape for alpha-emitting isotopes, particularly as demand has outpaced supply among rivals facing similar challenges. The company is exposed to commercialization and pricing risks, which could hinder its ability to compete effectively, especially if it cannot secure favorable pricing or reimbursement for its products. Furthermore, observed adverse events from clinical data, such as high rates of anemia and decreased lymphocyte counts, raise concerns about the safety profile of its therapies, potentially affecting patient adoption and overall market performance.

CATX has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Perspective Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Perspective Therapeutics Inc (CATX) Forecast

Analysts have given CATX a Strong Buy based on their latest research and market trends.

According to 8 analysts, CATX has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Perspective Therapeutics Inc (CATX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.